题名 | Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial | 链接 | https://pubmed.ncbi.nlm.nih.gov/37591292/ |
https://pubmed.ncbi.nlm.nih.gov/37591292/ |